Support road.cc

Like this site? Help us to make it better.

TECH NEWS

Bella Ciao partner cancer charity

Donation made with every sale from the women's city bike lineup

Retailers Bikesales4u have announced that a percentage of sales from their Bella Ciao ladies city bikes will be donated to the Against Breast Cancer charity.

Against Breast Cancer funds unique research with the aim of finding information to increase survival after diagnosis, and ultimately to discover a vaccine against breast cancer.

The Bella Ciao range of handmade Italian bikes includes the Corvo Citta Donna (from £599), a classic-looking step though design; the Neorealista (£899), a luxury lightweight; and, from the end of the year, the limited edition Moscova (price not yet set), an all-chrome, lightweight city bike. See the full range at www.bikesales4u.com.

In addition to the fundraising partnership, Bikesales4u are hoping to introduce the charity’s supporters to the Bella Ciao range while Against Breast Cancer expect to attract cyclists to their events.

We reported a couple of months ago how Forme were donating a proportion of every bike sale towards Marie Curie Cancer Care. This, along with all the work done by the the Lance Armstrong Foundation, suggests that the fight against cancer is the cycling world's worthy cause of choice.

Mat has been in cycling media since 1996, on titles including BikeRadar, Total Bike, Total Mountain Bike, What Mountain Bike and Mountain Biking UK, and he has been editor of 220 Triathlon and Cycling Plus. Mat has been road.cc technical editor for over a decade, testing bikes, fettling the latest kit, and trying out the most up-to-the-minute clothing. He has won his category in Ironman UK 70.3 and finished on the podium in both marathons he has run. Mat is a Cambridge graduate who did a post-grad in magazine journalism, and he is a winner of the Cycling Media Award for Specialist Online Writer. Now over 50, he's riding road and gravel bikes most days for fun and fitness rather than training for competitions.

Latest Comments